Intercept Announces New PBC Data Analyses to be Presented at Digestive Disease Week 2024 Conference

MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abstracts on primary biliary cholangitis (PBC) will be presented at Digestive Disease Week (DDW) 2024. The conference will be held from May 18-21 in Washington, D.C.

“We are pleased to participate in this year’s DDW and share our latest findings, including new data from our Phase 2 trial evaluating a fixed-dose combination of obeticholic acid and bezafibrate in patients with PBC,” said Sangeeta Sawhney, Senior Vice President and Head of U.S. Research & Development. “These data, along with new analyses from our landmark Phase 3 POISE trial, showcase our continued commitment to helping improve the lives of people living with PBC. We’re looking forward to sharing these data with the scientific community and learning about the latest in liver research.”

Presentations by Intercept at DDW 2024 include:

Oral Presentations
“Metabolic Outcomes and Key Efficacy Data From a Phase 2 Trial Evaluating Combination Obeticholic Acid and Bezafibrate in Patients With Primary Biliary Cholangitis” Session Number: 2395 (Abstract #155)
Saturday, May 18, 2:00 – 2:15 PM ET
Alan Bonder; David Jones; Cynthia Levy; Heng Zou; Antonio Civitarese; Fredrik Nevens

“Effect of Obeticholic Acid on APRI Score in Patients at Higher Risk for Fibrosis, as Determined by Higher Baseline Fibrosis-4 Score and Liver Stiffness: Sub-analysis of the Phase 3 POISE Trial in Primary Biliary Cholangitis” Session Number: 2395 (Abstract #156)
Saturday, May 18, 2:15 – 2:30 PM ET
Alan Bonder; Darren Wheeler; Jing Li; Christopher Gasink; Robert G. Gish

“Effect of Obeticholic Acid on Normalization of Alanine Aminotransferase and Aspartate Aminotransferase: Sub-analysis of the Phase 3 POISE Trial in Primary Biliary Cholangitis” Session Number: 4120 (Abstract #632)
Monday, May 20, 8:45 – 9:00 AM ET
Robert G. Gish; Darren Wheeler; Jing Li; Christopher Gasink; David W. Victor III

Poster Presentations
“Safety Analysis of the Current US Prescribing Information–Indicated Population From the HEROES Study of Obeticholic Acid in Patients With Primary Biliary Cholangitis” Session Number: 8240 (Abstract #1582)
Monday, May 20, 12:30 – 1:30 PM ET
Gideon Hirschfield; M. Alan Brookhart; Michael Fried; Leona Bessonova; Julia Chu; Darren Wheeler; Bettina Hansen; John Seeger; Sangeeta Sawhney; David Jones